Stay updated on Lebrikizumab in Atopic Dermatitis Clinical Trial
Sign up to get notified when there's something new on the Lebrikizumab in Atopic Dermatitis Clinical Trial page.

Latest updates to the Lebrikizumab in Atopic Dermatitis Clinical Trial page
- Check4 days agoChange DetectedAdded a new publication reference to the Publications section: 'Lebrikizumab is Efficacious in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Regardless of Atopic Comorbidities' (Ann Allergy Asthma Immunol, 2025). The DOI is 10.1016/j.anai.2025.12.017.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe Study Details page updated its Locations list with many new sites across the US, Australia, Canada, and Europe, and removed several existing locations.SummaryDifference2%

- Check25 days agoNo Change Detected
- Check40 days agoChange DetectedPublications section now includes a note that items are auto-filled from PubMed, and the Revision tag was updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check47 days agoChange DetectedRemoved the government funding/operating status notice from the page.SummaryDifference0.2%

- Check54 days agoChange Detected- Added a new publication to the Publications section: 'Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis' (Clin Exp Dermatol. 2025 Nov 8).SummaryDifference0.0%

- Check69 days agoChange DetectedNo substantive changes detected in the study details between the screenshots; only minor formatting or UI adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

Stay in the know with updates to Lebrikizumab in Atopic Dermatitis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lebrikizumab in Atopic Dermatitis Clinical Trial page.